C2N Diagnostics expands PrecivityAD2 Alzheimer’s test to ages 50+

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

C2N Diagnostics has widened the intended use of its PrecivityAD2™ Alzheimer’s disease blood test to include patients aged 50 and older, down from its previous threshold of 60, according to the company. This expansion follows successful additional validation studies, the company said, now allowing clinicians to prescribe the test for individuals born in 1975 or earlier. The blood test assists healthcare professionals in detecting amyloid plaques—key indicators of Alzheimer’s pathology—and informs clinical management and treatment decisions.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE